This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen/Ionis Spinraza Granted Marketing Authorization in EU
by Zacks Equity Research
Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.
Biogen's Fampyra Conditional Approval Converted to Standard
by Zacks Equity Research
Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
Ionis (IONS) Stock Falls Despite Positive Inotersen Data
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M
by Zacks Equity Research
Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).
Here's Why Shares of Ionis Pharma (IONS) are Falling Today
by Madeleine Johnson
On Monday, shares of Ionis Pharmaceuticals Inc. (IONS) are falling, down about 10% in morning trading after the company announced results from its 15-month long Phase 3 Neuro-TTR Study of its drug Inotersen (IONIS-TTRrx).
Ionis Pharmaceuticals (IONS) Beats on Q1 Earnings
by Indrajit Bandyopadhyay
Ionis reported earnings of 3 cents including stock based compensation which surpassed the Zacks Consensus Estimate of loss of 4 cents
4 Drug Stocks Poised to Beat this Earnings Season
by Zacks Equity Research
M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.
What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?
by Zacks Equity Research
Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.
Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11
Why Ionis (IONS) Might Surprise This Earnings Season
by Zacks Equity Research
Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Ionis (IONS) this Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.
Ionis Pharma Lipid Disorder Candidate Positive in Phase III
by Zacks Equity Research
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Ionis Pharmaceuticals (IONS) Beats on Q4 Earnings
by Zacks Equity Research
Ionis reported earnings of 21 cents including stock based compensation. However, excluding stock based compensation the company reported earnings of 33 cents that surpassed the Zacks Consensus Estimate of loss of 20 cents.
Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.
Ionis Pharmaceuticals (IONS) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) has been struggling lately, but the selling pressure may be coming to an end soon
Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017
by Zacks Equity Research
We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.
Biogen (BIIB) Presents Positive Phase III Data on Spinraza
by Zacks Equity Research
Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
by Zacks Equity Research
Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.
Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data
by Zacks Equity Research
Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.
Company News for December 28, 2016
by Zacks Equity Research
Companies in the News are: TSLA,PCRFY,IONS,TOSYY,FACU,AMZN
Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) announced that FDA has approved Spinraza under Priority Review for the treatment of spinal muscular atrophy.
Ionis Receives $5 Million Milestone from J&J Unit for GI Drug
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).
Biogen Names Commercial Officer as New CEO, Shares Fall
by Zacks Equity Research
Biogen Inc. (BIIB) has appointed its present chief commercial officer (CCO), Michel Vounatsos, as the new chief executive officer (CEO), effective Jan 6, 2017.
Ionis (IONS) Receives Milestone Payment from AstraZeneca
by Zacks Equity Research
Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.
Top Stocks with Big Potential Catch-Up Moves
by Kevin Matras
Given the recent run-up in the market, here's a screen I've been using recently.